Targeted Therapies for Metastatic Chromophobe Renal Cell Carcinoma
Posted: Tuesday, June 27, 2017
Based on the findings of reportedly the largest retrospective cohort to date of patients with metastatic chromophobe renal cell carcinoma treated with targeted therapy, Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, Villejuif, France, and colleagues found no significant difference in outcomes between antiangiogenic and mTOR inhibitors. The results of the Renal Cross Channel Group study were published in the European Journal of Cancer.
Of the 61 patients from 26 centers who received targeted therapy, 50 (82%) were given antiangiogenic inhibitors and 11 were given mTOR inhibitors. The median follow-up from the date of first metastasis was 6.1 years.
For patients treated with a first line of antioangiogenic inhibitors, the time to treatment failure and overall survival were 8.7 months and 22.9 months, respectively. For patients treated with a first line of mTOR inhibitors, the time to treatment failure and overall survival were 1.9 months and 3.2 months, respectively. Based on the stratified log-rank test comparison of treatments, no significant difference was observed for time to treatment failure (P=.26) or overall survival (P=.55).